Patient baseline clinical and demographic details: data are expressed and number (%) or mean±SD
| Baseline clinical characteristics | n=26 |
|---|---|
| Age (years) | 25±8 |
| Male | 14 (54%) |
| F508 del homozygous | 15 (58%) |
| BMI (kg/m2) | 21±3 |
| CFRD | 8 (31%) |
| Pancreatic insufficiency | 25 (96%) |
| Inhaled steroids | 21 (81%) |
| Long-term azithromycin | 25 (96%) |
| Long-term nebulised antibiotics | 25 (96%) |
| Triazole therapy >3 months prior to enrolment | 2 (8%) |
| Chronic Pseudomonas | 26 (100%) |
| Chronic Burkholderia spp | 1 (4%) |
| Chronic MSSA | 9 (35%) |
| Chronic MRSA | 0 (0%) |
| NTM | 1 (4%) |
| FEV1% predicted | 42±15 |
| FVC % predicted | 59±17 |
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; NTM, non-tuberculous mycobacteria.